Cargando…

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis

The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gang...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Kyu, Jung, Su Woong, Moon, Ju-Young, Jeong, Kyung Hwan, Hwang, Hyeon Seok, Kim, Jin Sug, Lee, Sang-Ho, Kang, So-Young, Kim, Yang Gyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207316/
https://www.ncbi.nlm.nih.gov/pubmed/35734170
http://dx.doi.org/10.3389/fimmu.2022.894700
_version_ 1784729500115795968
author Kim, Dae Kyu
Jung, Su Woong
Moon, Ju-Young
Jeong, Kyung Hwan
Hwang, Hyeon Seok
Kim, Jin Sug
Lee, Sang-Ho
Kang, So-Young
Kim, Yang Gyun
author_facet Kim, Dae Kyu
Jung, Su Woong
Moon, Ju-Young
Jeong, Kyung Hwan
Hwang, Hyeon Seok
Kim, Jin Sug
Lee, Sang-Ho
Kang, So-Young
Kim, Yang Gyun
author_sort Kim, Dae Kyu
collection PubMed
description The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gangdong Kyung Hee University Hospital and Kyung Hee Medical Center and 100 hospital workers from Gangdong Kyung Hee University Hospital were enrolled in this study. The HD patients received the mixing schedule of ChAdOx1/BNT162b2 vaccinations at 10-week intervals, while hospital workers received two doses of ChAdOx1 vaccines at 12-week intervals. Serum IgG to a receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 was measured 1 month after the first dose, 2 months and 4 months after the second dose. The median [interquartile range] anti-RBD IgG was 82.1[34.5, 176.6] AU/ml in HD patients and 197.1[124.0, 346.0] AU/ml in hospital workers (P < 0.001) after the first dose. The percentage of positive responses (IgG > 50 AU/ml) was 65.0% and 96.0% among the both group, respectively (P < 0.001). The anti-RBD IgG levels increased significantly by 2528.8 [1327.6, 5795.1] AU/ml with a 100.0% positive response rate in HD patients 2 months after the second dose, which was higher than those in hospital workers 981.4[581.5, 1891.4] AU/ml (P < 0.001). Moreover, anti-RBD IgG remains constantly high, and positive response remains 100% in HD patients 4 months after the second dose. This study suggests that heterologous vaccinations with ChAdOx1/BNT162b2 can be an alternative solution on HD patients for early and strong induction of humoral response.
format Online
Article
Text
id pubmed-9207316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92073162022-06-21 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis Kim, Dae Kyu Jung, Su Woong Moon, Ju-Young Jeong, Kyung Hwan Hwang, Hyeon Seok Kim, Jin Sug Lee, Sang-Ho Kang, So-Young Kim, Yang Gyun Front Immunol Immunology The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gangdong Kyung Hee University Hospital and Kyung Hee Medical Center and 100 hospital workers from Gangdong Kyung Hee University Hospital were enrolled in this study. The HD patients received the mixing schedule of ChAdOx1/BNT162b2 vaccinations at 10-week intervals, while hospital workers received two doses of ChAdOx1 vaccines at 12-week intervals. Serum IgG to a receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 was measured 1 month after the first dose, 2 months and 4 months after the second dose. The median [interquartile range] anti-RBD IgG was 82.1[34.5, 176.6] AU/ml in HD patients and 197.1[124.0, 346.0] AU/ml in hospital workers (P < 0.001) after the first dose. The percentage of positive responses (IgG > 50 AU/ml) was 65.0% and 96.0% among the both group, respectively (P < 0.001). The anti-RBD IgG levels increased significantly by 2528.8 [1327.6, 5795.1] AU/ml with a 100.0% positive response rate in HD patients 2 months after the second dose, which was higher than those in hospital workers 981.4[581.5, 1891.4] AU/ml (P < 0.001). Moreover, anti-RBD IgG remains constantly high, and positive response remains 100% in HD patients 4 months after the second dose. This study suggests that heterologous vaccinations with ChAdOx1/BNT162b2 can be an alternative solution on HD patients for early and strong induction of humoral response. Frontiers Media S.A. 2022-06-06 /pmc/articles/PMC9207316/ /pubmed/35734170 http://dx.doi.org/10.3389/fimmu.2022.894700 Text en Copyright © 2022 Kim, Jung, Moon, Jeong, Hwang, Kim, Lee, Kang and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kim, Dae Kyu
Jung, Su Woong
Moon, Ju-Young
Jeong, Kyung Hwan
Hwang, Hyeon Seok
Kim, Jin Sug
Lee, Sang-Ho
Kang, So-Young
Kim, Yang Gyun
Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title_full Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title_fullStr Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title_full_unstemmed Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title_short Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
title_sort severe acute respiratory syndrome coronavirus 2 antibody response after heterologous immunizations with chadox1/bnt162b2 in end-stage renal disease patients on hemodialysis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207316/
https://www.ncbi.nlm.nih.gov/pubmed/35734170
http://dx.doi.org/10.3389/fimmu.2022.894700
work_keys_str_mv AT kimdaekyu severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT jungsuwoong severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT moonjuyoung severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT jeongkyunghwan severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT hwanghyeonseok severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT kimjinsug severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT leesangho severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT kangsoyoung severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis
AT kimyanggyun severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis